Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27104235 | 0.78 | DRD4 (0.34) | DRD4DRD2HDAC8PDE10A | |
| SCHEMBL18237954 | 0.76 | DRD4 (0.46) | DRD4DRD2 | |
| SCHEMBL19129893 | 0.75 | DRD4 (0.37) | DRD4DRD2PDE10A | |
| SCHEMBL27106924 | 0.75 | DRD4 (0.37) | DRD4DRD2PDE10A | |
| SCHEMBL18199156 | 0.75 | DRD4 (0.37) | DRD4DRD2PDE10A | |
| SCHEMBL27106923 | 0.75 | DRD4 (0.37) | DRD4DRD2PDE10A | |
| SCHEMBL18237632 | 0.74 | DRD4 (0.35) | DRD4DRD2 | |
| SCHEMBL18238055 | 0.74 | DRD4 (0.38) | DRD4DRD2HDAC9PDE10A | |
| SCHEMBL22548958 | 0.74 | MAOA (0.40) | DRD4DRD2PDE10A | |
| SCHEMBL21483644 | 0.74 | DRD4 (0.48) | DRD4DRD2HDAC8RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076297-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | US | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| EP-3672971-B1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | BOEHRINGER INGELHEIM INT (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10968225-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA | 2021-04-06 | — | — | US | disclosed |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200369663-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2020-11-26 | — | — | US | disclosed |
| US-8779153-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130203802-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | DRD4 1648/4885DRD2 1442/4885HDAC8 4780/4885 |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | DRD4 4679/4885DRD2 4708/4885HDAC8 1330/4885 |
| US-20240076297-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | DRD4 3143/4885DRD2 1382/4885HDAC8 2111/4885 |
| US-20130203802-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | DRD4 1142/4885DRD2 1210/4885HDAC8 2638/4885 |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | DRD4 3022/4885DRD2 4273/4885HDAC8 3430/4885 |
| US-20200369663-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC1 | DRD4 4679/4885DRD2 4603/4885HDAC8 3590/4885 |
| US-10968225-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC1 | DRD4 4679/4885DRD2 4603/4885HDAC8 3590/4885 |
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | INMT, IDO1, CHRM1 | DRD4 380/4885DRD2 694/4885HDAC8 4175/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | DRD4 4858/4885DRD2 4856/4885HDAC8 1068/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | DRD4 4770/4885DRD2 4763/4885HDAC8 974/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | DRD4 2725/4885DRD2 4227/4885HDAC8 1954/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | DRD4 4116/4885DRD2 4049/4885HDAC8 251/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | DRD4 2725/4885DRD2 4227/4885HDAC8 1954/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | DRD4 2725/4885DRD2 4227/4885HDAC8 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.